DOCSLIB.ORG

Sorrento Therapeutics, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sorrento Therapeutics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.14a-12 Sorrento Therapeutics, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ ☒ ☐ ☐ • Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ☐ ☐ ☐ ☐ (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 4955 Directors Place San Diego, California 92121 NOTICE OF 2018 ANNUAL MEETING OF STOCKHOLDERS AND PROXY STATEMENT Dear Stockholder: On behalf of our Board of Directors, I cordially invite you to attend the annual meeting of stockholders of Sorrento Therapeutics, Inc. (the “Company”) to be held at the offices of Paul Hastings LLP, 4747 Executive Drive, San Diego, California 92121 on August 24, 2018 at 12:00 p.m. Pacific Time, for the following purposes: 1. To elect six (6) directors for a one-year term to expire at the 2019 annual meeting of stockholders; 2. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018; 3. To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; 4. To approve an amendment to the Company’s Restated Certificate of Incorporation to eliminate restrictions on removal of directors; and 5. To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof. Our board of directors has fixed July 16, 2018 as the record date for the determination of stockholders entitled to notice of, and to vote at, the annual meeting and at any adjournment or postponement of the meeting. We intend to mail this proxy statement and the accompanying proxy card on or about July 24, 2018 to all stockholders of record entitled to vote at the Annual Meeting. If You Plan to Attend Please note that space limitations make it necessary to limit attendance of the Annual Meeting to our stockholders. Registration and seating will begin at 11:30 a.m. Pacific Time. Shares of common stock can be voted at the Annual Meeting only if the holder thereof is present in person or by valid proxy. For admission to the Annual Meeting, each stockholder may be asked to present valid picture identification, such as a driver’s license or passport, and proof of stock ownership as of the record date, such as the enclosed proxy card or a brokerage statement reflecting stock ownership. Cameras, recording devices and other electronic devices will not be permitted at the Annual Meeting. If you do not plan on attending the Annual Meeting, please vote, date and sign the enclosed proxy and return it in the business envelope provided. Even if you do plan to attend the Annual Meeting, we recommend that you vote your shares at your earliest convenience in order to ensure your representation at the Annual Meeting. Your vote is very important. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on August 24, 2018 at 12:00 p.m. Pacific Time at the offices of Paul Hastings LLP, 4747 Executive Drive, San Diego, California 92121. The proxy statement and annual report to stockholders are available at http://www.pstvote.com/sorrento2018. By the Order of the Board of Directors /s/ Henry Ji Henry Ji, Ph.D. Chairman of the Board, President and Chief Executive Officer Dated: July [•], 2018 Whether or not you expect to attend the Annual Meeting in person, we urge you to vote your shares at your earliest convenience. This will ensure the presence of a quorum at the Annual Meeting. Promptly voting your shares will save the Company the expenses and extra work of additional solicitation. An addressed envelope for which no postage is required if mailed in the United States is enclosed if you wish to vote by mail. Submitting your proxy now will not prevent you from voting your shares at the Annual Meeting if you desire to do so, as your proxy is revocable at your option. Your vote is important, so please act today! If you have questions or need assistance voting your shares please contact: Innisfree M&A Incorporated 501 Madison Avenue, 20th Floor New York, NY 10022 Stockholders in the U.S. and Canada please call toll-free: (888) 750-5834 Stockholders in other locations please call: + (412) 232-3651 Banks and Brokers may call collect: (212) 750-5833 TABLE OF CONTENTS Page QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING 2 PROPOSAL 1: ELECTION OF DIRECTORS 9 PROPOSAL 2: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 23 PROPOSAL 3: ADVISORY VOTE TO APPROVE THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS 26 PROPOSAL 4: APPROVAL OF AN AMENDMENT TO THE COMPANY’S RESTATED CERTIFICATE OF INCORPORATION 27 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 29 EXECUTIVE COMPENSATION 34 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 52 SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE 54 EQUITY COMPENSATION PLAN INFORMATION 54 ADDITIONAL INFORMATION 55 OTHER MATTERS 56 APPENDIX A - CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION 59 4955 Directors Place San Diego, California 92121 PROXY STATEMENT FOR THE 2018 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 24, 2018 The Board of Directors (the “Board”) of Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) is soliciting your proxy to vote at the Annual Meeting of Stockholders (the “Annual Meeting”) to be held at the offices of Paul Hastings LLP, 4747 Executive Drive, San Diego, California 92121, on August 24, 2018 at 12:00 p.m. Pacific Time, including at any adjournments or postponements of the Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card if you received paper copies of the proxy materials, or follow the instructions below to submit your proxy over the Internet. We intend to mail this proxy statement and the accompanying proxy card on or about July 24, 2018 to all stockholders of record entitled to vote at the Annual Meeting. 1 QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING How do I attend the Annual Meeting? The Annual Meeting will be held on August 24, 2018, at 12:00 p.m. Pacific Time at the offices of Paul Hastings LLP, 4747 Executive Drive, San Diego, California 92121. Information on how to vote in person at the Annual Meeting is discussed below. Who is Entitled to Vote? The Board has fixed the close of business on July 16, 2018 as the record date (the “Record Date”) for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. As of July 16, 2018, there were [•] shares of common stock outstanding. Each share of common stock represents one vote that may be voted on each proposal that may come before the Annual Meeting. What is the Difference Between Holding Shares as a Record Holder and as a Beneficial Owner (Holding Shares in Street Name)? If your shares are registered in your name with our transfer agent, Philadelphia Stock Transfer, Inc., you are the “record holder” of those shares. If you are a record holder, these proxy materials have been provided directly to you by the Company. If your shares are held in a stock brokerage account, a bank or other holder of record, you are considered the “beneficial owner” of those shares held in “street name.” If your shares are held in street name, these proxy materials have been forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to instruct this organization on how to vote your shares. Who May Attend the Annual Meeting? Only record holders and beneficial owners of our common stock, or their duly authorized proxies, may attend the Annual Meeting. If your shares of common stock are held in street name, you will need to bring a copy of a brokerage statement or other documentation reflecting your stock ownership as of the Record Date. What am I Voting on? There are four matters scheduled for a vote: 1. To elect six (6) directors for a one-year term to expire at the 2019 annual meeting of stockholders; 2. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018; 3. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and 4.
Load more

Recommended publications
  • SCRIPPS DISCOVERS FALL 2010 Selective Inhibition of BMK1 Suppresses Tumor Growth
    SC RIPPS DISC OVERS Accelerating Discoveries, Saving Lives A Newsletter for Philanthropists Published Quarterly by The Scripps Research Institute WINTER 2010 | VOL 7 | NO 1 California-Florida RESEARCH UPDATE Scripps Research Scientists Develop Molecular Test Providing a New Pathway for Identifying Obesity and Diabetes Drugs cientists at The Scripps Research Institute The Worm Institute for Research and Medicine have designed a new molecular test that at Scripps Research. Swill allow researchers to look for potential Janda and Amanda Garner, Ph.D., a research drugs targeting a human metabolic enzyme believed associate in his laboratory, described the new to stimulate the appetite and play a role in diabetes. approach—which may also prove useful for The new test, which the scientists call a simple investigating other enzymes involved in a assay, will allow researchers to look through variety of diseases—in an advance, online Early hundreds of thousands of compounds for those that Edition of the journal Angewandte Chemie on have potential to block the action of an enzyme September 15, 2010. known as ghrelin O-acyltransferase (GOAT). If Even though GOAT was only discovered drugs can be found that safely suppress the action recently, in 2008, scientists had speculated for of GOAT, they may help people who have clinical years that it had to exist. After all, its target (ghrelin, problems with appetite, obesity, and diabetes. or the “G” in the acronym GOAT) had been Professor Kim Janda “There hasn’t been a simple screen until now,” known for more than a decade. says Kim D. Janda, Ph.D., a professor in the Ghrelin, a small peptide hormone that is Departments of Chemistry and Immunology mainly produced in the stomach, signals hunger, and Microbial Science, member of The Skaggs typically before meals.
    [Show full text]
  • Dr. Craig W. Lindsley, FRSC
    Dr. Craig W. Lindsley, FRSC Home Address: Laboratory Address I: Laboratory Address II: 9281 Wardley Park Lane Department of Pharmacology VCNDD – Cool Springs Brentwood, TN 37027 MRBIV (Langford), 12478B Innovation Park (615)-891-1470 Vanderbilt Medical Center 393 Nichol Mills Road Nashville, TN 37232-6600 Franklin, TN 37027 E-mail: [email protected]; phone (office): 615-322-8700 Web sites: www.lindsleylab.com; www.vcndd.org; www.appellopharma.com Citizenship: US Date of Birth: February 7, 1970 Marital status: Married (Stacey), six children: Cameron (13), Jayma (11), Paige (10), Madison (6), Logan (4), Luke (2) Education: 1997 – 1999 Postdoctoral Fellow, Harvard University, Cambridge, MA 1992 - 1996 Ph.D., University of California, Santa Barbara, Santa Barbara, CA 1988 - 1992 B.S., Chemistry, California State University, Chico, Chico, CA Academic Appointments, Industrial Positions, Leadership Roles and Research Experience: 01/2018-present University Professor of Chemistry, University Professor of Pharmacology, University Professor of Biochemistry William K. Warren, Jr. Chair in Medicine, Co-Director and Director of Medicinal Chemistry and DMPK, Vanderbilt Center for Neuroscience Drug Discovery; Site Head, VCNDD Cool Springs Innovation Park; Editor-in-Chief, ACS Chemical Neuroscience Member, Vanderbilt Institute of Chemical Biology, VU-Ingram Cancer Center, Vanderbilt Center for Addiction Research Vanderbilt University School of Medicine, Vanderbilt University (Medicinal Chemistry, Drug Discovery, Total Synthesis, Chemical Biology)
    [Show full text]
  • ACNP 57Th Annual Meeting: Panels, Mini-Panels and Study Groups
    www.nature.com/npp ABSTRACTS COLLECTION ACNP 57th Annual Meeting: Panels, Mini-Panels and Study Groups Sponsorship Statement: Publication of this supplement is sponsored by the ACNP. Individual contributor disclosures may be found within the abstracts. Asterisks in the author lists indicate presenter of the abstract at the annual meeting. https://doi.org/10.1038/s41386-018-0265-8 Panel experiments were performed in 8-10-week-old male or female mice on a C57 background. 1. Dissecting the Contributions of Dopamine D1 and D2 Results: We observed dendritic atrophy in NAc D1-MSNs but Receptor-Expressing Neurons in Behaviors Dysregulated in not D2-MSNs in CSDS susceptible mice (P < 0.001). mRNAs of RhoA Neuropsychiatric Illness pathway molecules were significantly altered in D1-MSNs of CSDS susceptible mice (P < 0.05). Genetic overexpression of WT-RhoA in D1-MSNs induced dendritic atrophy and a susceptible outcome to 1.1 Dichotomous Structural Adaptations in Nucleus SSDS (P < 0.01), while DN-RhoA in D1-MSNs restored dendritic Accumbens Neuron Subtypes Underlie Stress Susceptibility complexity and caused a resilient outcome to CSDS (P < 0.05) compared to eYFP controls. RhoA (WT) in D1-MSNs caused reduced time grooming in splash test of female mice, reduced Mary Kay Lobo sucrose preference in male mice, and enhanced time immobile in forced swim test of both sexes (P < 0.05). Increased Egr3, the RhoA University of Maryland School of Medicine, Baltimore, Maryland, transcriptional regulator, in D2-MSNs promotes stress resiliency (P United States < 0.05) by preventing D2-MSN enhanced density of mushroom spines that occurs in stress susceptible mice (P < 0.01), without Background: Ventral striatum (nucleus accumbens-NAc) medium altering dendritic arbor.
    [Show full text]
  • SRI C20-5 Endeavor
    VOLUME EIGHT NUMBER ONE EndeavorSpring 2005 Controlling Addiction Endeavor VOLUME EIGHT NUMBER ONE Spring 2005 Addiction takes an enormous toll on individuals, families, and society as a whole. The direct and indirect public health costs of addiction are estimated to be in the hundreds of billions of dollars yearly. What are the biological bases of addiction? How can we Sandbagging Cancer in the more effectively treat and prevent this terrible disease? This issue Bloodstream of Endeavor features some investigators at The Scripps Research Institute who are helping to answer these questions. A team of scientists led by Scripps Research Institute Professor David A. Cheresh and Research Associate Sara Weis has identified a potential treatment strategy against metastatic cancer cells that has never been tried before. featured page Metastasis is a major problem with cancer because it allows tumor cells to spread to other parts of the body. While solid tumors can be removed surgically or treated An Antidote for Addiction 02 with chemotherapy or radiation, metastatic cells that Kim Janda Uses the Immune System to Fight Drug Abuse have already entered the circulation are capable of opening a passageway through blood vessels in order to spread to various organs throughout the body. The treatment strategy, which showed promise in the Working to Understand the lab, targets a final step of the metastatic cascade—the Brain’s Role in Alcohol Dependence 06 exit of the metastatic cells from the bloodstream— George Koob and Barbara Mason Search for increasing the protective barrier strength of the host Treatments That Work Over the Long-Term blood vessels and preventing tumor cells from exiting the bloodstream to establish a new cancer site.
    [Show full text]
  • Director's Report
    ``` DIRECTOR’S REPORT to the National Advisory Council on Drug Abuse September 2020 Nora D. Volkow, M.D. Director National Institute on Drug Abuse TABLE OF CONTENTS RESEARCH HIGHLIGHTS ............................................................................................................ 1 GRANTEE HONORS AND AWARDS ......................................................................................... 23 STAFF HONORS AND AWARDS ................................................................................................ 25 STAFF CHANGES .......................................................................................................................... 26 IN MEMORIAM .............................................................................................................................. 33 RESEARCH HIGHLIGHTS BASIC AND BEHAVIORAL RESEARCH Structure Of The Neurotensin Receptor 1 In Complex With β-arrestin 1 Huang W, Masureel M, Qianhui Q, Janetzko J, Asuka I, Kato HE, Robertson MJ, Nguyen KC, Glenn JS, Skiniotis G, Kobilka BK. Nature. March 2020. 579:303-308. Arrestin proteins bind to active, phosphorylated G-protein-coupled receptors (GPCRs), thereby preventing G-protein coupling, triggering receptor internalization and affecting various downstream signalling pathways. Although there is a wealth of structural information detailing the interactions between GPCRs and G proteins, less is known about how arrestins engage GPCRs. Here we report a cryo-electron microscopy structure of full-length human neurotensin receptor
    [Show full text]
  • Feasibility, Rationale and Prospects for Therapeutic Cocaine Vaccines
    James Shearer & Richard P. Mattick Feasibility, rationale and prospects for therapeutic cocaine vaccines NDARC Technical Report No. 168 FEASIBILITY, RATIONALE AND PROSPECTS FOR THERAPEUTIC COCAINE VACCINES James Shearer & Richard P. Mattick Technical Report Number 168 ISBN: 1 877027 56 1 THIS REPORT WAS FUNDED BY THE AUSTRALIAN GOVERNMENT DEPARTMENT OF HEALTH AND AGEING ©NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2003. 2 TABLE OF CONTENTS EXECUTIVE SUMMARY...................................................................................................4 ACKNOWLEDGEMENTS..................................................................................................5 1. BACKGROUND TO COCAINE USE.......................................................................6 1.1 Prevalence of cocaine use ................................................................................6 1.2 Nature of cocaine harms..................................................................................6 1.3 Treatment for cocaine use disorders...............................................................7 2. INTRODUCTION TO COCAINE VACCINES ..........................................................8 2.1 General principles of immunotherapy ............................................................8 2.2 Rationale ...........................................................................................................8 2.3 Mechanism........................................................................................................9
    [Show full text]
  • The Scripps Research Institute
    FALL 2006 VOLUME NINE / NUMBER TWO NON-PROFIT U.S. POSTAGE PAID PERMIT 751 SAN DIEGO, CA THE SCRIPPS RESEARCH INSTITUTE A PUBLICATION OF THE SCRIPPS RESEARCH INSTITUTE Office of Communications—TPC30 ENDEAVOR 10550 North Torrey Pines Road La Jolla, California 92037 www.scripps.edu PUBLISHER: Keith McKeown EDITOR: Mika Ono Benedyk DESIGN: Miriello Grafico PRODUCTION: Miriello Grafico Kevin Fung COVER ILLUSTRATION: Carey Sookocheff PORTRAIT PHOTOGRAPHY: Dana Neibert Bruce Hibbs PRINTING: Precision Litho © 2006 All material copyrighted by The Scripps Research Institute. “What’s important is the work these people are doing. They should have the glory.” HELEN DORRIS Donor Profile: Helen Dorris THE SCRIPPS RESEARCH INSTITUTE Helen Dorris is part of the Scripps Research family. Busy researchers greet her in the hallway and stop to discuss current projects. More than a sup- ENDEAVOR porter, she is their friend. Helen takes a keen interest in the neurosciences and has helped bring several researchers to Scripps Research to explore the mysteries of Alzheim- er’s, schizophrenia, and other brain disorders. VOLUME NINE / NUMBER TWO FALL 2006 She is proud of the research she supports but shies away from taking any credit. “What’s important is the work these people are doing,” she says. “They should have the glory.” 17 Helen Dorris has made several gifts of real estate to Scripps Research to establish a fellowship to study schizophrenia and to create both the Helen L. FEATURES: ALSO: Dorris Child and Adolescent Neuro-Psychiatric Disorder Institute and the Harold L. Dorris Neurological Research Institute. BEHIND THE SCENES The institutes, now the home of some of the world’s top brain research- ers, uncover the pathological basis of neurological and psychiatric disorders and expedite the discovery of promising new therapeutic approaches.
    [Show full text]
  • Scientists Design Nicotine Vaccine That Provokes Robust Immune Response 12 January 2015
    Scientists design nicotine vaccine that provokes robust immune response 12 January 2015 When a promising nicotine vaccine failed in clinical that it did not single out the most common form of trials a few years ago, scientists from The Scripps nicotine for attack. Nicotine has two forms that look Research Institute (TSRI) were determined to keep like mirror images of each other—one is a "right- trying to help smokers overcome their addiction. handed" version and one is a "left-handed" version. Even though 99 percent of the nicotine found in Now the team has designed a more effective tobacco is the left-handed version, the previous nicotine vaccine and proven that the structures of vaccine elicited antibodies against both. molecules used in vaccines is critical. The study was published recently in the Journal of Medicinal Janda believes that was a waste of immune Chemistry. response. "This is a case where something very simple was overlooked," he said. "This study provides new hope that one could make a nicotine vaccine that succeeds in clinical Improving the Response trials," said Kim Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs In the new study, the researchers elicited a more Institute for Chemical Biology at TSRI. robust antibody response by creating a vaccine from only left-handed nicotine haptens. To do this, Targeting Nicotine they prepared haptens as a 50-50 mixture and as pure right-handed or pure left-handed versions of According to the National Cancer Institute, nicotine, so they could use the two versions smoking is the leading cause of eight types of together or separately.
    [Show full text]
  • 21 September 2012 | $10 CREDIT: MIKE KEMP/GETTY IMAGES SPECIALSECTION
    21 September 2012 | $10 CREDIT: MIKE KEMP/GETTY IMAGES SPECIALSECTION Disease INTRODUCTION Prevention CONTENTS It Takes More Than News 1468 Task Force’s Prevention Advice an Apple a Day Proves Hard to Swallow Public Health Measures in Disease Prevention AS MODELS FOR PREVENTION RESEARCH, INFECTIOUS DISEASES HAVE SET A HIGH standard. Thanks to the development and widespread distribution of vaccines and 1471 Will an Aspirin a Day Keep Cancer anti microbial drugs, we now live in a world free of smallpox, nearly free of polio, Away? Wondering How the Wonder Drug Works and with declining rates of malaria and AIDS. These victories (some still partial) have resulted in people living longer and acute infectious diseases being super- 1473 Tackling America’s Eating Habits, seded in many countries as a public health priority by long-term noncommuni- One Store at a Time cable diseases. Heart disease, metabolic disease, cancer, and respiratory disease 1476 Uncertain Verdict as Vitamin D together account for 60% of all deaths worldwide and 80% of deaths in low- and Goes On Trial middle-income countries. Global projections for dementia are particularly alarm- 1479 Chronic Disease Vaccines Need ing: By the year 2050, the disorder may affect more than 100 million people. Shot in the Arm Logic dictates that preventing these diseases is a better approach than treat- Review ing people after they have become ill. In many cases, the knowledge and tools needed for prevention appear to be in place. A number of these killer diseases 1482 Can Noncommunicable Diseases share risk factors that can be modifi ed by lifestyle changes—for example, by Be Prevented? Lessons from Studies of Populations and Individuals eliminating tobacco use, eating less processed food, and increasing physical M.
    [Show full text]
  • Director's Report 2/96
    Director's Report 2/96 Director's Report to the National Advisory Council on Drug Abuse February, 1996 Index Research Findings Basic Research Behavioral Research Clinical & Services Research AIDS Research Epidemiology, Etiology and Prevention Research Intramural Research Program Activities Congressional Affairs International Activities Meetings/Conferences Media and Education Activities Planned Meetings Publications Staff Highlights Grantee Honors [Office of Director] [First Report Section] Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? _ See our Contact Information. https://archives.drugabuse.gov/DirReports/DirRep296/DirectorRepIndex.html[11/16/16, 8:31:17 PM] Director's Report 2/96 - Basic Research Director's Report to the National Advisory Council on Drug Abuse February, 1996 Research Findings Basic Research Cocaine Immunization Kim Janda, Ph.D., Rocio Carrera, M.A., George Koob, Ph.D. and colleagues at the Scripps Research Institute have demonstrated, for the first time, the ability to immunize rats against some of the stimulant effects of cocaine. The animals were treated for 35 days with a conjugated analog of cocaine that is more resistant to metabolism by esterases and that is recognized by the body as a foreign substance. Antibodies were produced in the rats which prevented the subsequent administration of cocaine from producing its CNS stimulatory effects. Cocaine levels in the brains of these animals were reduced from 50 to 75% from those of rats not subjected to the 35-day pretreatment regimen.
    [Show full text]
  • Cv Roberto.Pdf
    CURRICULUM VITAE Personal Details Name: Marisa Roberto Home Address: 3950 Mahaila Avenue, Apt U23, San Diego, California 92122 Work Address: Department of Neuroscience, SP30-1150, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. Contact Details: Tel: (858) 784-7262; Fax: (858) 784-7405 E-mail: [email protected] Education: B.A. equivalent 1991-1996: University of Pisa (Italy); Degree: Biological Sciences; 110/110 cum laude Title of experimental thesis: "Mechanisms of modulation of the Na+/K+-ATPasic pump in the T neurons of the leech Hirudo medicinalis by a sea-weed biotoxin.” PhD 1997-2001: University of Pisa (Italy) and The Scripps Research Institute (USA). May 4 2001: Title of experimental PhD thesis: “The neuropeptide PACAP-38 and ethanol alter the synaptic transmission in rat CA1 hippocampal slices.” Laboratory experience: 1994-1996: Electrophysiology laboratory (research group of Prof. M. Brunelli), Department of Physiology and Biochemistry, University of Pisa, Pisa, Italy. August-December 1996: Leonardo da Vinci UETP (University Enterprises Training Partnership) Fellowship Trainee, Neuronal Development and Biochemistry, The Brabraham Institute of Cambridge, UK, (advisor: Prof. Simon Luckman). 1996-1997: Lab training (advisors: Profs. M. Brunelli and A. Felicioli). February 1997-May 2001: PhD in “Basic Neuroscience,” Department of Physiology and Biochemistry, University of Pisa, Italy (advisor: Prof. M. Brunelli). February-December 1999: PhD Fellowship Training, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA (advisors: Profs: G.R. Siggins and D.L. Gruol). May 2001-2003: Postdoctoral Fellowship, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA (advisor: Prof. G.R. Siggins).
    [Show full text]
  • ON the BORDER Info & Insights from the Interface Between Energy Healing & Science
    ON THE BORDER Info & insights from the interface between energy healing & science April 2016 Welcome to the April 2016 edition of 'On the Border'.. For those of you new to ‘On the Border’, this is Jayne's monthly Ezine newsletter about the latest information and insights into energy fields, healing and science. Each month I share with you some of the latest research and how it applies to healing, energy work & (daily) life. There is also a 'Freebie' section where you get something for nothing, gratis. Are you wanting to learn the basics of healing and energy work? There is a beginners ‘Heal! En jezelf ook’ in May- July (DEADLINE for registration is SATURDAY 30th APRIL). And the last Self- Healing Circle before the summer is upon us takes place on 25th April. Please consult Jayne’s Calendar below for details and links to the workshops and trainings I have planned for the coming few months. Immune to Addiction? WShen neuroscientist George Koob proposed creating a vaccine for addiction 25 years ago, his colleagues thought he was wasting his time. The immune system evolved to prevent infections, not highs from illegal drugs. Prevailing wisdom holds that treating addiction requires months or years of psychotherapy to help addicts change their thought patterns, a difficult process that does not consistently work. But Koob, then at the Scripps Research Institute, wanted addicts to be able to see their doctor for a shot that could keep them from getting high when their motivation to stay clean waned. His premise was simple. Vaccines against infectious diseases work by priming the body to produce antibodies that stick to the invading pathoge, preventing it from causing illness.
    [Show full text]